Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03688503 · ClinicalTrials.gov registry record · NA
Magnesium Supplementation and Blood Pressure Reduction
A NA study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 59
- Enrollment target
NCT03688503 is a NA study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 59 participants.
The verdict
NCT03688503, a NA study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 59 participants
- Enrollment target
Study Summary
This double-blind, placebo-controlled randomized clinical trial will test whether a magnesium glycinate supplement (480 mg/day) taken for 12 weeks lowers blood pressure.
Interventions
- DIETARY_SUPPLEMENT magnesium glycinate supplement
- DIETARY_SUPPLEMENT placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2019-02-15 |
| Est. Completion | 2025-08-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03688503
The ClinicalTrials.gov registry entry for NCT03688503 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which magnesium glycinate supplement is the first listed.
NCT03688503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03688503 about?
NCT03688503 is a clinical study titled "Magnesium Supplementation and Blood Pressure Reduction". This double-blind, placebo-controlled randomized clinical trial will test whether a magnesium glycinate supplement (480 mg/day) taken for 12 weeks lowers blood pressure.
What is the current status of trial NCT03688503?
This trial is currently completed. It is a NA study. The enrollment target is 59 participants. The study started on 2019-02-15. Estimated completion is 2025-08-15.
What interventions are being tested in trial NCT03688503?
The interventions under investigation include: magnesium glycinate supplement (DIETARY_SUPPLEMENT), placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03688503?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.